PTC Therapeutics price target lowered to $51 from $53 at JPMorgan

JPMorgan lowered the firm’s price target on PTC Therapeutics to $51 from $53 and keeps an Overweight rating on the shares. The company’s Q2 results were largely in line with expectations, the analyst tells investors in a research note. The firm continues to view PTC shares at an attractive entry point into “multiple near-term value-accretive catalysts.”